According to a market research report, approximately 19.05 million deaths worldwide were attributed to cardiovascular disease (CVD) in 2022. Data from the American Heart Association (AHA) indicates that the global vascular stent market is expected to reach $22.69 billion by 2030, with a compound annual growth rate (CAGR) exceeding 6.0%.

HeXun Biosciences and JY BioMed have signed an exclusive licensing agreement for “Human-Derived Umbilical Cord Mesenchymal Stem Cell Drug Production Technology.” Following the licensing of related production technology for human umbilical cord mesenchymal stem cells (UC-MSCs) to JY BioMed, both parties will collaborate to develop specific MSC-derived exosomes using specialized techniques and data.

HeXun Biosciences (6986), a company listed on the Emerging Stock Market, has recently reached a new milestone in its operations. HeXun has signed a "Mesenchymal Stem Cell Drug - Production Technology" licensing agreement with JY BioMed. HeXun will provide JY BioMed with its umbilical cord-derived mesenchymal stem cell (UC-MSC) culture technology and exosome production technology.

HeXun Biosciences and JY BioMed have signed an exclusive licensing agreement for “Human-Derived Umbilical Cord Mesenchymal Stem Cell Drug Production Technology.” Following the licensing of related production technology for human umbilical cord mesenchymal stem cells (UC-MSCs) to JY BioMedical, both parties will collaborate to develop specific MSC-derived exosomes using specialized techniques and data.

Dendritic cells (DCs) are powerful antigen-presenting cells crucial for initiating immune responses. DC-based tumor vaccines have been shown to safely stimulate anti-tumor-associated antigen (TAA) responses, as exemplified by Sipuleucel-T (Provenge), an FDA-approved autologous DC vaccine for castration-resistant prostate cancer. However, such vaccines have generally shown limited clinical efficacy, necessitating strategies to improve their effectiveness.